Published in Cardiology on January 01, 1979
Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet (1999) 8.53
Drug interactions with cimetidine. Clin Pharmacokinet (1982) 2.49
Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes (1999) 2.14
Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes (2007) 2.13
Impaired cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharmacol (1981) 1.86
The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest (1999) 1.72
Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Diabetes (1996) 1.51
Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials. Diabetes Obes Metab (2011) 1.47
Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol (1974) 1.46
Somatostatin suppresses secretin and pancreatic exocrine secretion. Science (1975) 1.45
Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet (1980) 1.42
Epinephrine secretion, hypoglycemia unawareness, and diabetic autonomic neuropathy. Ann Intern Med (1994) 1.41
Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. J Clin Endocrinol Metab (2001) 1.41
Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy. Ann Intern Med (1982) 1.41
Is radical scavenging necessary in the treatment of inflammatory bowel disease? Gastroenterology (1991) 1.39
[The duodenojejunal flexure--a gap in the routine diagnosis of gastrointestinal bleeding]. Dtsch Med Wochenschr (1999) 1.38
Hepatic ketogenesis and gluconeogenesis in humans. J Clin Invest (1974) 1.37
A reappraisal of caloric requirements in healthy women. Am J Clin Nutr (1986) 1.35
The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Clin Pharmacol Ther (1975) 1.33
Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet (1984) 1.32
Cimetidine for anastomotic ulcers after partial gastrectomy. A randomized controlled trial. N Engl J Med (1979) 1.32
Severe insulin-induced hypoglycemia associated with deficiencies in the release of counterregulatory hormones. N Engl J Med (1981) 1.30
A sensitive double antibody radioimmunoassay for human growth hormone (HGH): levels of serum HGH following rapid tolbutamide infusion. Diabetologia (1967) 1.29
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology (1985) 1.29
Cimetidine plasma concentration-response relationships. Clin Pharmacol Ther (1981) 1.29
Energy metabolism in feasting and fasting. Adv Exp Med Biol (1979) 1.24
Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem Soc Trans (2003) 1.24
Effect of smoking on duodenal ulcer healing with cimetidine and oxmetidine. Gut (1982) 1.22
Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol (1975) 1.21
Increased human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells induced by ethanol: potential immunopathogenic mechanisms. J Infect Dis (1996) 1.19
Thermic effect of food in lean and obese men. J Clin Invest (1988) 1.18
Carbohydrate oxidation and storage in obese non-insulin-dependent diabetic patients. Effects of improving glycemic control. Diabetes (1983) 1.18
Objective and subjective evaluation of photic phenomena after monofocal and multifocal intraocular lens implantation. Ophthalmology (1999) 1.15
Rapid intravenous sodium acetoacetate infusion in man. Metabolic and kinetic responses. J Clin Invest (1973) 1.15
Effect of hyperinsulinemia on urea pool size and substrate oxidation rates. Diabetes (1988) 1.14
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Preparation and specificity of antiserum to synthetic secretin and its use in a radioimmunoassay (RIA). Endocrinology (1973) 1.13
Effects of intraduodenal amino acids, fatty acids, and sugars on secretin concentrations. Gastroenterology (1975) 1.12
Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab (2007) 1.11
Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther (1983) 1.09
Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol (1978) 1.08
Ketosis of starvation: a revisit and new perspectives. Clin Endocrinol Metab (1983) 1.08
A test of the hypothesis that the rate of fall in glucose concentration triggers counterregulatory hormonal responses in man. Diabetes (1977) 1.07
Inhibition of human liver cytochrome P-450 by omeprazole. Br J Clin Pharmacol (1986) 1.06
Elevated serum human growth hormone and decreased serum insulin in prediabetic males after intravenous tolbutamide and glucose. J Clin Invest (1968) 1.04
Pharmacokinetics of ketamine in man. Anaesthesist (1975) 1.03
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet (1980) 1.02
Effects of therapy on the nature and quantity of fuels oxidized during diabetic ketoacidosis. Diabetes (1980) 1.02
Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. J Clin Invest (1981) 1.00
Ethanol causes acute inhibition of carbohydrate, fat, and protein oxidation and insulin resistance. J Clin Invest (1988) 1.00
Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res (1984) 0.99
Quantitation of glycolysis and skeletal muscle glycogen synthesis in humans. Am J Physiol (1993) 0.99
Splanchnic somatostatin: a hormonal regulator of nutrient homeostasis. Science (1980) 0.98
HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet (2005) 0.98
Effects of intraduodenal administration of HCl and glucose on circulating immunoreactive secretin and insulin concentrations. J Clin Invest (1974) 0.97
Does smoking interfere with the effect of histamine H2-receptor antagonists on intragastric acidity in man? Gut (1987) 0.97
Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995. Lancet (1986) 0.96
Acetone metabolism during diabetic ketoacidosis. Diabetes (1982) 0.96
Prevention of postprandial hypotension with somatostatin. Ann Intern Med (1985) 0.96
Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol (1979) 0.95
In vivo and in vitro effects of antiinsulin receptor antibodies. J Clin Endocrinol Metab (1984) 0.95
Monitoring metabolic control in diabetic outpatients with glycosylated hemoglobin. Ann Intern Med (1980) 0.95
Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. N Engl J Med (1986) 0.95
Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes (2011) 0.95
Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest (1983) 0.94
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Fuel metabolism during pregnancy. Semin Reprod Endocrinol (1999) 0.93
Relapsing polychondritis with insulin resistance and antibodies to cartilage. Am J Med (1973) 0.93
Longitudinal study of carbohydrate metabolism in healthy obese pregnant women. Diabetes Care (1997) 0.93
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Intraocular pressure after small incision cataract surgery: temporal sclerocorneal versus clear corneal incision. J Cataract Refract Surg (2001) 0.92
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Inflammation after sclerocorneal versus clear corneal tunnel phacoemulsification. Ophthalmology (2000) 0.91
Identification, characterization, and distribution of secretin immunoreactivity in rat and pig brain. Proc Natl Acad Sci U S A (1981) 0.91
Long-term effects of dietary fiber on glucose tolerance and gastric emptying in noninsulin-dependent diabetic patients. Am J Clin Nutr (1983) 0.91
Influence of thyroid status on plasma half-life of antipyrine in man. N Engl J Med (1974) 0.90
Characterization of immunoreactive components of insulin and somatostatin in canine pancreatic juice. FEBS Lett (1979) 0.90
Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur J Clin Pharmacol (1982) 0.90
Omeprazole inhibits elimination of diazepam. Lancet (1984) 0.90
Substrate, hormone, and temperature responses in males and females to a common breakfast. Metabolism (1980) 0.90
Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs. Br J Clin Pharmacol (1980) 0.90
Free fatty acids and insulin resistance during pregnancy. J Clin Endocrinol Metab (1998) 0.90
Resting metabolic rate and body composition of achondroplastic dwarfs. Medicine (Baltimore) (1990) 0.89
Clofibrate kinetics after single and multiple doses. Clin Pharmacol Ther (1978) 0.89
Assessment of norepinephrine secretion and production. J Lab Clin Med (1983) 0.89
Contrast sensitivity and glare disability by halogen light after monofocal and multifocal lens implantation. Br J Ophthalmol (2000) 0.88
In vivo interactions between H2-receptor antagonists and ethanol metabolism in man and in rats. Hepatology (1985) 0.88
Effects of glucagon on plasma amino acids. J Clin Invest (1984) 0.88
Effect of short hairpin RNA-mediated adiponectin/Acrp30 down-regulation on insulin signaling and glucose uptake in the 3T3-L1 adipocytes. J Endocrinol Invest (2009) 0.88
[Familial dwarfism with disproportionately high vertebral bodies]. Humangenetik (1972) 0.87
Effect of clofibrate on the metabolism of bilirubin, bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilbert's syndrome. Clin Sci (Lond) (1984) 0.87
Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes (1999) 0.87
Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. Eur J Clin Pharmacol (1984) 0.87
Human splanchnic metabolism during diabetic ketoacidosis. Metabolism (1977) 0.87
Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. Biochem Pharmacol (1985) 0.86
Managing insulin-dependent diabetic patients. Postgrad Med (1976) 0.86